Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer

Circulating IL-6, an activator of JAK/STAT signaling, is associated with poor prognosis and aromatase inhibitor (AI) resistance in hormone-receptor positive (HR+) breast cancer. Here we report the results of a phase 2 single-arm Simon 2-stage trial combining Ruxolitinib, an oral selective inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Makhlin, Igor, McAndrew, Nicholas P., Wileyto, E. Paul, Clark, Amy S., Holmes, Robin, Bottalico, Lisa N., Mesaros, Clementina, Blair, Ian A., Jeschke, Grace R., Fox, Kevin R., Domchek, Susan M., Matro, Jennifer M., Bradbury, Angela R., Feldman, Michael D., Hexner, Elizabeth O., Bromberg, Jacqueline F., DeMichele, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652412/
https://www.ncbi.nlm.nih.gov/pubmed/36369506
http://dx.doi.org/10.1038/s41523-022-00487-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652412/
https://www.ncbi.nlm.nih.gov/pubmed/36369506
http://dx.doi.org/10.1038/s41523-022-00487-x

Ejemplares similares